M T Madon Exports Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: M T Madon Exports Pharmaceutical Export Portfolio Dataset — 6 Products, $75.8K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

M T Madon Exports — Pharmaceutical Exporter Profile (2026) | 6 Products, $75.8K Trade | TransData Nexus

M T Madon Exports

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $75.8K Total Trade · DGFT Verified

M T Madon Exports is an Indian pharmaceutical exporter with a total trade value of $75.8K across 6 products in 4 therapeutic categories. Based on 53 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Mitomycin ($36.2K), Sulfasalazine ($20.6K), Ibrutinib ($11.7K).

M T Madon Exports — Export Portfolio & Destination Treemap

M T Madon Exports pharmaceutical export portfolio — 6 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is M T Madon Exports? — Company Overview & Market Position

M T Madon Exports, established on August 30, 1997, is a proprietary firm based in Mumbai, Maharashtra, India. The company specializes in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Over the years, it has built a reputation for delivering quality pharmaceutical products to various international markets. The firm's registered office is located at 23, Pinjari Street, 346 A.R. Street, Crawford Market, Mumbai 400003, India.

As of March 2026, M T Madon Exports operates as a small enterprise under the MSME classification for the financial year 2024-25. The company is registered under the Goods and Services Tax (GST) with the number 27AABFM1239Q1ZZ, indicating its active status and compliance with Indian tax regulations.

What Does M T Madon Exports Export? — Product Portfolio Analysis

Top Products by Export Value

1Mitomycin$36.2K 2Sulfasalazine$20.6K

Product Portfolio — Top 6 by Export Value

M T Madon Exports exports 6 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Mitomycin	Advanced Oncology	$36.2K	18	0.4%	11
2	Sulfasalazine	Gastrointestinal	$20.6K	7	0.6%	12
3	Ibrutinib	Advanced Oncology	$11.7K	12	1.2%	13
4	Streptomycin	Antibiotics	$2.9K	5	0.5%	8
5	Canagliflozin	Advanced Diabetes Medications	$2.6K	4	0.3%	11
6	Repaglinide	Advanced Diabetes Medications	$1.7K	7	0.0%	9

M T Madon Exports exports 6 pharmaceutical products across 4 therapeutic categories with a total export value of $75.8K. The top category is Advanced Oncology (63.2% of portfolio), followed by Gastrointestinal (27.2%), indicating a concentrated portfolio with the top 5 products accounting for 97.7% of total export value.

M T Madon Exports — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding M T Madon Exports' manufacturing facilities are not publicly disclosed. The company primarily focuses on the export of finished pharmaceutical formulations, suggesting that it may source products from various manufacturers rather than producing them in-house. This approach allows the firm to offer a diverse range of products without the complexities associated with manufacturing operations.

3Key Leadership

The principal executive and proprietor of M T Madon Exports is Mr. Kamlesh P. Shah. His leadership has been instrumental in steering the company towards its current position in the pharmaceutical export sector. Under his guidance, the firm has established a strong presence in international markets, particularly in regions such as Africa and Southeast Asia.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does M T Madon Exports Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

M T Madon Exports has demonstrated a consistent presence in regulated markets, particularly in Africa. The company has engaged in multiple shipments to countries like Kenya, exporting pharmaceutical products such as Pantocid IV 40mg Injection. These transactions indicate the company's adherence to international standards and its ability to navigate the regulatory landscapes of these markets.

2Emerging Markets

M T Madon Exports has made significant inroads into emerging markets, notably in Africa and Southeast Asia. The company's export activities in these regions underscore its commitment to expanding its global footprint and meeting the pharmaceutical needs of developing economies. By leveraging the World Health Organization's prequalification program, M T Madon Exports ensures that its products meet international quality standards, facilitating smoother market access in these regions.

3Geographic Strategy

M T Madon Exports' geographic strategy appears to be focused on diversification, with a notable emphasis on emerging markets in Africa and Southeast Asia. This approach mitigates concentration risk and positions the company to capitalize on growth opportunities in regions with increasing demand for pharmaceutical products. The strategic direction suggests a long-term commitment to global expansion and market penetration.

M T Madon Exports — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding M T Madon Exports' interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, is not publicly available. This lack of transparency may indicate limited or no direct engagement with the U.S. market.

2WHO & EU GMP

There is no publicly available information confirming that M T Madon Exports holds World Health Organization (WHO) prequalification or European Union Good Manufacturing Practice (EU GMP) certificates. The absence of such certifications may impact the company's ability to access certain international markets that require these standards.

3CDSCO & Indian Regulatory

M T Madon Exports operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds the necessary manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian pharmaceutical regulations. Additionally, M T Madon Exports possesses the required export No Objection Certificates (NOCs), facilitating its international trade activities.

M T Madon Exports — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

M T Madon Exports operates in a competitive landscape with several key players in the pharmaceutical export sector. While specific market share data is not publicly available, the company's focus on emerging markets in Africa and Southeast Asia positions it to compete effectively by offering quality products tailored to the needs of these regions. The firm's ability to navigate diverse regulatory environments and establish partnerships with local distributors enhances its competitive edge.

2Key Differentiators

M T Madon Exports' key differentiators include its strategic focus on emerging markets, particularly in Africa and Southeast Asia, and its ability to offer a diverse range of pharmaceutical products. The company's commitment to quality and compliance with international standards, as evidenced by its export activities, further distinguishes it in the marketplace.

3Strategic Position

M T Madon Exports' current strategic direction emphasizes expansion into emerging markets, leveraging its expertise in pharmaceutical exports to meet the growing demand in these regions. The company's future outlook appears positive, with opportunities to enhance its product portfolio and strengthen its market presence through strategic partnerships and adherence to international quality standards.

Buyer Due Diligence Brief — Evaluating M T Madon Exports as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

M T Madon Exports has demonstrated a consistent track record in exporting pharmaceutical products, with a total export value of $76,000 USD across 53 shipments. The company's reliability is further evidenced by its ongoing partnerships with international buyers, indicating a stable and dependable supply chain. The firm's focus on quality and compliance with international standards enhances its reputation as a trustworthy supplier.

2Certifications to Verify

Importers should verify the following certifications when considering M T Madon Exports as a supplier:

FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. regulations.

WHO Prequalification: Verify if the company's products are prequalified by the World Health Organization, indicating adherence to international quality standards.

Frequently Asked Questions — M T Madon Exports

How many pharmaceutical products does M T Madon Exports export from India?

M T Madon Exports exports 6 pharmaceutical products across 4 therapeutic categories. The top exports are Mitomycin ($36.2K), Sulfasalazine ($20.6K), Ibrutinib ($11.7K), Streptomycin ($2.9K), Canagliflozin ($2.6K). Total export value is $75.8K.

What is M T Madon Exports's total pharmaceutical export value?

M T Madon Exports's total pharmaceutical export value is $75.8K, based on 53 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does M T Madon Exports cover?

M T Madon Exports exports across 4 therapeutic categories. The largest are Advanced Oncology (63.2%, 2 products), Gastrointestinal (27.2%, 1 products), Advanced Diabetes Medications (5.7%, 2 products).

Get Full M T Madon Exports Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.